Respiratory syncytial virus (RSV) affects people across the lifespan, with infants and older adults experiencing the highest risk of severe disease and hospitalisation. New vaccines, prevention products and funded programs are now available in Australia, creating important opportunities to reduce RSV illness and its impact.
This webinar provided an evidence-based overview of the evolving RSV immunisation landscape, including:
- disease burden, with a focus on older adults
- RSV immunisation products, including data on effectiveness, safety and uptake
- national, state and territory RSV prevention programs
- real‑world case studies and tips for discussing RSV vaccination
- practical considerations for implementing RSV immunisation, including co‑administration and approaches to minimising errors
- a live Q&A with experts.